000143436 001__ 143436
000143436 005__ 20240229112553.0
000143436 0247_ $$2doi$$a10.1182/bloodadvances.2018015966
000143436 0247_ $$2pmid$$apmid:30948364
000143436 0247_ $$2pmc$$apmc:PMC6457221
000143436 0247_ $$2ISSN$$a2473-9529
000143436 0247_ $$2ISSN$$a2473-9537
000143436 0247_ $$2ISSN$$a2476-9537
000143436 0247_ $$2altmetric$$aaltmetric:58644767
000143436 037__ $$aDKFZ-2019-01024
000143436 041__ $$aeng
000143436 082__ $$a610
000143436 1001_ $$0P:(DE-He78)2fe44044f40217387daaf299f2eb7340$$aCosta, Barbara Maria$$b0$$eFirst author$$udkfz
000143436 245__ $$aIntratumoral platelet aggregate formation in a murine preclinical glioma model depends on podoplanin expression on tumor cells.
000143436 260__ $$aWashington, DC$$bAmerican Society of Hematology$$c2019
000143436 3367_ $$2DRIVER$$aarticle
000143436 3367_ $$2DataCite$$aOutput Types/Journal article
000143436 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1555309825_28575
000143436 3367_ $$2BibTeX$$aARTICLE
000143436 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000143436 3367_ $$00$$2EndNote$$aJournal Article
000143436 500__ $$aDKFZ-ZMBH Alliance
000143436 520__ $$aBinding of the sialomucin-like transmembrane glycoprotein podoplanin (PDPN) to the platelet receptor C-type lectin-like receptor 2 induces platelet activation and aggregation. In human high-grade gliomas, PDPN is highly expressed both in tumor cells and in tumor-associated astrocytes. In glioma patients, high expression of PDPN is associated with worse prognosis and has been shown to correlate with intratumoral platelet aggregation and an increased risk of venous thromboembolism (VTE). To functionally assess the role of PDPN in platelet aggregation in vivo, we established a syngeneic orthotopic murine glioma model in C57/Bl6 mice, based on transplantation of p53- and Pten-deficient neural stem cells. This model is characterized by the presence of intratumoral platelet aggregates and by the upregulation of PDPN both in glioma cells and in astrocytes, reflecting the characteristics of human gliomas. Deletion of PDPN either in tumor cells or in astrocytes resulted in glioma formation with similar penetrance and grade compared with control mice. Importantly, only the lack of PDPN in tumor cells, but not in astrocytes, caused a significant reduction in intratumoral platelet aggregates, whereas in vitro, both cell types have similar platelet aggregation-inducing capacities. Our results demonstrate a causative link between PDPN and platelet aggregation in gliomas and pinpoint the tumor cells as the major players in PDPN-induced platelet aggregation. Our data indicate that blocking PDPN specifically on tumor cells could represent a novel strategy to prevent platelet aggregation and thereby reduce the risk of VTE in glioma patients.
000143436 536__ $$0G:(DE-HGF)POF3-311$$a311 - Signalling pathways, cell and tumor biology (POF3-311)$$cPOF3-311$$fPOF III$$x0
000143436 588__ $$aDataset connected to CrossRef, PubMed,
000143436 7001_ $$0P:(DE-He78)db396aa5e7017ae96520ba81ded5fc0e$$aEisemann, Tanja$$b1$$udkfz
000143436 7001_ $$aStrelau, Jens$$b2
000143436 7001_ $$0P:(DE-HGF)0$$aSpaan, Ingrid$$b3
000143436 7001_ $$0P:(DE-He78)8d9c904a6cea14d4c99c78ba46e41f93$$aKorshunov, Andrey$$b4$$udkfz
000143436 7001_ $$0P:(DE-HGF)0$$aLiu, Hai-Kun$$b5
000143436 7001_ $$aBugert, Peter$$b6
000143436 7001_ $$0P:(DE-He78)f4f068e71e0d87bf0ad51e6214ab84e9$$aAngel, Peter$$b7$$udkfz
000143436 7001_ $$0P:(DE-He78)2727b5cb63b52d0137d4f4e8f110ee7e$$aPeterziel, Heike$$b8$$eLast author$$udkfz
000143436 773__ $$0PERI:(DE-600)2876449-3$$a10.1182/bloodadvances.2018015966$$gVol. 3, no. 7, p. 1092 - 1102$$n7$$p1092 - 1102$$tBlood advances$$v3$$x2473-9537$$y2019
000143436 909CO $$ooai:inrepo02.dkfz.de:143436$$pVDB
000143436 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)2fe44044f40217387daaf299f2eb7340$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000143436 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)db396aa5e7017ae96520ba81ded5fc0e$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000143436 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000143436 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8d9c904a6cea14d4c99c78ba46e41f93$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000143436 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000143436 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f4f068e71e0d87bf0ad51e6214ab84e9$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000143436 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)2727b5cb63b52d0137d4f4e8f110ee7e$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000143436 9131_ $$0G:(DE-HGF)POF3-311$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vSignalling pathways, cell and tumor biology$$x0
000143436 9141_ $$y2019
000143436 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000143436 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central
000143436 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000143436 915__ $$0StatID:(DE-HGF)0112$$2StatID$$aWoS$$bEmerging Sources Citation Index
000143436 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000143436 9201_ $$0I:(DE-He78)A100-20160331$$kA100$$lSignaltransduktion/Wachstumskontrolle$$x0
000143436 9201_ $$0I:(DE-He78)B300-20160331$$kB300$$lKKE Neuropathologie$$x1
000143436 9201_ $$0I:(DE-He78)A240-20160331$$kA240$$lMolekulare Neurogenetik$$x2
000143436 980__ $$ajournal
000143436 980__ $$aVDB
000143436 980__ $$aI:(DE-He78)A100-20160331
000143436 980__ $$aI:(DE-He78)B300-20160331
000143436 980__ $$aI:(DE-He78)A240-20160331
000143436 980__ $$aUNRESTRICTED